Investor Relations

(Security Code :4506 TSE Prime)

Pick Up

Apr. 08, 2026	Notice Regarding Issuance of New Shares and Secondary Offering of Shares	Finances
Apr. 08, 2026	Notice Regarding Refinancing of Existing Borrowings through a Bridge Loan	Finances
Mar. 30, 2026	Sumitomo Pharma Submits Partial Change Application in Japan to Add Pediatric Dosage and Administration for LATUDA in Schizophrenia	R&D
Mar. 25, 2026	Notice Concerning Non-operating Income Recorded in the Company’s Non-consolidated Financial Statements (Japanese GAAP)	Finances
Mar. 06, 2026	Announcement on the Approval for Manufacturing and Marketing Authorization of the Allogeneic iPS Cell-Derived Dopaminergic Neural Progenitor Cell Product “AMCHEPRY” in Japan	Products
Mar. 04, 2026	Posted Conference on Boost 2028 - Accelerating Strong Sumitomo Pharma - [Webcast]	Finances

May 13, 2026	FY2025 financial results announcement (scheduled to be disclosed at 1:00 p.m.), conference on financial results FY2025 for Analysts, Investors, and the Press